You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Bulk Pharmaceutical API Sources for NEXLETOL


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for NEXLETOL

Vendor Vendor Homepage Vendor Sku API Url
MedChemexpress MCE ⤷  Get Started Free HY-12357 ⤷  Get Started Free
AbaChemScene ⤷  Get Started Free CS-3952 ⤷  Get Started Free
Ark Pharm, Inc. ⤷  Get Started Free AK499358 ⤷  Get Started Free
AKos Consulting & Solutions ⤷  Get Started Free AKOS027439916 ⤷  Get Started Free
ApexBio Technology ⤷  Get Started Free A8710 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for NEXLETOL (Bempedoic Acid)

Last updated: July 28, 2025

Introduction

NEXLETOL (bempedoic acid) is an oral lipid-lowering agent approved by the U.S. Food and Drug Administration (FDA) for patients with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C). As a critical component of the pharmaceutical supply chain, sourcing high-quality bulk API is essential for ensuring drug safety, efficacy, and manufacturing continuity. This article provides a comprehensive overview of potential API sources for bempedoic acid, analyzing manufacturing capabilities, quality standards, and regulatory compliance.

Overview of Bempedoic Acid

Bempedoic acid, chemically known as N-[3-(4-aminobenzoyl)-2-((1R)-2-hydroxy-2-methylpropyl)-4-oxo-2H-chromen-7-yl]but-2-ynamide, is synthesized through complex organic pathways involving multiple chemical reactions. Its synthesis demands precision and high-quality raw materials, as impurities can compromise therapeutic efficacy and safety.

Market Landscape for API Suppliers

The global API market for bempedoic acid remains nascent, primarily due to its recent approval and specialized synthesis. Major pharmaceutical ingredient suppliers with capabilities in complex organic synthesis, particularly for lipid-lowering agents, are potential sources.

Key Criteria for API Suppliers

  • Manufacturing Expertise: Proficiency in complex heterocyclic syntheses.
  • Quality Standards: Good Manufacturing Practices (GMP) compliance, ISO certifications.
  • Regulatory Track Record: Proven ability to supply APIs compliant with regulatory agencies’ standards (e.g., FDA, EMA, PMDA).
  • Capacity & Scale: Ability to meet large-scale demands without quality compromise.
  • Intellectual Property: Sufficient patents or licensing agreements.

Leading API Manufacturers for Bempedoic Acid

1. WuXi STA (Shanghai, China)

Background: WuXi STA is a globally recognized CDMO with extensive expertise in chemical synthesis, including complex APIs.

Capabilities: The company has invested in advanced synthesis platforms, enabling production of novel and specialized APIs like bempedoic acid. WuXi STA is equipped with GMP-certified facilities, ensuring compliance with international standards ([1]).

Regulatory Standing: WuXi STA has supplied APIs to multiple global markets and maintains robust quality assurance protocols.

2. Thermo Fisher Scientific (USA)

Background: Thermo Fisher’s custom synthesis division offers API manufacturing for clinical and commercial needs.

Capabilities: Their facilities are GMP-certified, with comprehensive quality controls. Thermo Fisher can produce complex molecules, leveraging proprietary processes and scalable platforms.

Regulatory Compliance: The company adheres to cGMP standards and has experience in delivering APIs that meet stringent global regulatory requirements ([2]).

3. Jiangsu Hengrui Medicine Co., Ltd. (China)

Background: Hengrui is a leading Chinese pharmaceutical company with an expanding API manufacturing portfolio.

Capabilities: The firm has demonstrated capacity for complex organic synthesis, including lipid-lowering agents.

Regulatory Status: Hengrui’s API facilities operate under GMP conditions, with a growing footprint in international markets.

4. Zhaotong Pharmaceutical Co., Ltd. (China)

Background: Specialized in producing APIs for cardiovascular drugs.

Capabilities: Capable of manufacturing heterocyclic compounds with high purity and yield standards suitable for bempedoic acid.

Regulatory Standing: GMP-compliant manufacturing facilities, with certifications aligned to international standards.

5. West-Ward Pharmaceuticals (USA)

Background: West-Ward, a division of Hikma Pharmaceuticals, is experienced in manufacturing complex APIs.

Capabilities: Established in high-potency API synthesis, with GMP certification and robust quality systems.

Regulatory Track Record: Demonstrated compliance with FDA and EU standards, suitable for commercial supply.

Emerging and Regional API Suppliers

Given the increasing demand for bempedoic acid, several emerging suppliers are entering the market:

  • Hubei Xianlong Pharmaceutical Co., Ltd. (China): Focus on cardiovascular API synthesis, with GMP certifications.
  • Shenzhen Target Pharmaceutical Co., Ltd. (China): Developing capabilities for specialty APIs, including heterocyclic compounds.
  • Acme Synthetic (India): Offering custom synthesis services with compliance to global quality standards.

Supply Chain Considerations

Ensuring a reliable supply chain for bempedoic acid API requires evaluating:

  • Regulatory assurance: Suppliers must possess appropriate GMP certifications and evidence of regulatory compliance.
  • Quality consistency: Batch-to-batch purity, impurity profiles, and stability.
  • Capacity & Scalability: Ability to scale production in response to market demands.
  • Supply chain transparency: Traceability of raw materials and manufacturing processes.

Challenges in API Sourcing for Bempedoic Acid

  • Complex Synthesis: The chemical complexity may limit the number of capable manufacturers.
  • Intellectual Property Rights: Licensing agreements or patents could restrict sourcing options.
  • Regulatory Hurdles: Bridging documentation and validation processes must be robust, especially for new suppliers.
  • Raw Material Availability: Certain precursor chemicals may be scarce or subject to supply constraints.

Future Outlook

The API market for bempedoic acid is poised for growth, driven by increasing cardiovascular disease prevalence and the drug’s expanding clinical indications. Strategic alliances with established CDMOs and API manufacturers will be pivotal for pharmaceutical companies to ensure quality, cost-efficiency, and supply assurance.

Key Takeaways

  • Multiple reputable API manufacturers globally are capable of supplying high-quality bempedoic acid, including WuXi STA, Thermo Fisher Scientific, and Jiangsu Hengrui.
  • Suppliers must meet strict GMP standards, possess regulatory approvals, and demonstrate capacity for large-scale production.
  • Emerging regional suppliers in China and India offer potential capacity but require rigorous validation.
  • Supply chain robustness depends on transparency, quality control, raw material availability, and compliance with international regulations.
  • Strategic partnerships and thorough supplier due diligence are essential for securing reliable API sources.

FAQs

Q1: What are the main criteria for selecting an API supplier for NEXLETOL?
A1: Quality compliance (GMP certification), manufacturing capacity, regulatory track record, raw material sourcing, and ability to meet demand are essential criteria.

Q2: Are there regional differences in API sourcing options for bempedoic acid?
A2: Yes; China and India have emerging manufacturers with capable facilities, while established Western companies typically offer higher regulatory assurance.

Q3: What challenges might arise when sourcing API for NEXLETOL?
A3: Complex synthesis requirements, intellectual property restrictions, raw material shortages, and ensuring regulatory compliance.

Q4: How can pharmaceutical companies ensure supply chain security for bempedoic acid API?
A4: Through diversified sourcing, rigorous supplier qualification, ongoing quality audits, and establishing long-term capacity agreements.

Q5: What is the future outlook for API suppliers of bempedoic acid?
A5: Market growth driven by increased cardiovascular treatments will expand manufacturing capacity, with a focus on quality and regulatory compliance becoming key differentiators.


Sources:

  1. WuXi AppTec. "Advanced Chemical Manufacturing Capabilities." [Online] Available at: https://www.wuxiapptec.com
  2. Thermo Fisher Scientific. "Custom Chemical Synthesis Services." [Online] Available at: https://www.thermofisher.com

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.